Cytochrome P450 in GtoPdb v.2021.2 by Burns, Kathryn & Helsby, Nuala Ann
IUPHAR/BPS	Guide	to	Pharmacology	CITE
https://doi.org/10.2218/gtopdb/F242/2021.2
Cytochrome	P450	in	GtoPdb	v.2021.2
Kathryn	Burns1	and	Nuala	Ann	Helsby1
1.	 University	of	Auckland,	New	Zealand
Abstract
The	cytochrome	P450	enzyme	superfamily	(CYP),	E.C.	1.14.-.-,	are	haem-containing	monooxygenases
with	a	vast	range	of	both	endogenous	and	exogenous	substrates.	These	include	sterols,	fatty	acids,
eicosanoids,	fat-soluble	vitamins,	hormones,	pesticides	and	carcinogens	as	well	as	drugs.	Listed
below	are	the	human	enzymes,	their	relationship	with	rodent	CYP	enzyme	activities	is	obscure	in	that
the	species	orthologue	may	not	metabolise	the	same	substrates.	Some	of	the	CYP	enzymes	located	in
the	liver	are	particularly	important	for	drug	metabolism,	both	hepatic	and	extrahepatic	CYP	enzymes
also	contribute	to	patho/physiological	processes.	Genetic	variation	of	CYP	isoforms	is	widespread	and
likely	underlies	a	proportion	of	individual	variation	in	drug	disposition.	The	superfamily	has	the	root
symbol	CYP,	followed	by	a	number	to	indicate	the	family,	a	capital	letter	for	the	subfamily	with	a
numeral	for	the	individual	enzyme.	Some	CYP	are	able	to	metabolise	multiple	substrates,	others	are
oligo-	or	mono-	specific.
Contents
This	is	a	citation	summary	for	Cytochrome	P450	in	the	Guide	to	Pharmacology	database	(GtoPdb).	It
exists	purely	as	an	adjunct	to	the	database	to	facilitate	the	recognition	of	citations	to	and	from	the
database	by	citation	analyzers.	Readers	will	almost	certainly	want	to	visit	the	relevant	sections	of	the
database	which	are	given	here	under	database	links.
GtoPdb	is	an	expert-driven	guide	to	pharmacological	targets	and	the	substances	that	act	on	them.
GtoPdb	is	a	reference	work	which	is	most	usefully	represented	as	an	on-line	database.	As	in	any
publication	this	work	should	be	appropriately	cited,	and	the	papers	it	cites	should	also	be	recognized.
This	document	provides	a	citation	for	the	relevant	parts	of	the	database,	and	also	provides	a
reference	list	for	the	research	cited	by	those	parts.	For	further	details	see	[14].
Please	note	that	the	database	version	for	the	citations	given	in	GtoPdb	are	to	the	most	recent
preceding	version	in	which	the	family	or	its	subfamilies	and	targets	were	substantially	changed.	The
links	below	are	to	the	current	version.	If	you	need	to	consult	the	cited	version,	rather	than	the	most
recent	version,	please	contact	the	GtoPdb	curators.
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